| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d27415c4dbafeff331caf3aad9a8519 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57442
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2003-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43fb57701189c8aec4a1b9241090ac6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9e5b74a40b01184996bbbb04f6e07ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a702672399bca9a81aa74d860a972cfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc240b822fb8c1b2144ed73916ce255d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da50b51b7162773733b62600d38806b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9851ce3cc414640d313de679895910f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa0022d72afb7b7a8006ac95a4ff321a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84dffbfeb3249746a55ec5e4497fe360
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_706b84cb826bf8bce4b5b9a89687f89f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59cf090ab62052040f1ae4eadeaf8fad |
| publicationDate |
2005-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20050031589-A |
| titleOfInvention |
In Vitro Method and Kit for Detecting Cervical Cancer-associated HPV Infection |
| abstract |
The present invention relates to an in vitro immunostaining test for cervical cancer-associated HPV (Human papillomavirus) infection and to a kit for in vitro immunostaining for cervical cancer-related HPV infection, wherein the method of the present invention comprises (a) a raw sample comprising cells. Preparing; (b) inactivating endogenous peroxidase in the raw sample by treating the raw sample with H 2 O 2 ; (c) specifically treating said raw sample with a primary monoclonal antibody that is responsive to an antigen derived from cervical cancer-associated HPV; (d) specifically treating the raw sample with a retrieval system comprising a secondary antibody having a binding capacity to the primary antibody and having a peroxidase linked thereto; (e) immunostaining cells in the raw sample by treating the raw sample with a chromogenic substrate of the peroxidase linked to the secondary antibody; And (f) observing whether and how immunostained the cells infected with cervical cancer-associated HPV in the raw sample are. |
| priorityDate |
2003-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |